EASL recommendations on treatment of hepatitis C: Final update of the series☆
- PMID: 32956768
- DOI: 10.1016/j.jhep.2020.08.018
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Erratum in
-
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series' [J Hepatol 73 (2020) 1170-1218].J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1. J Hepatol. 2023. PMID: 36464532 No abstract available.
Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest Jean-Michel Pawlotsky: Grant and research support: Abbott, Vela Diagnostics. Advisory Boards: Abbvie, Arbutus, Gilead, GlaxoSmithKline, Merck, Regulus and Siemens Healthcare. Speaking and teaching: Abbvie and Gilead. Alessio Aghemo: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Alfasigma, Gilead, Intercept, Merck and Mylan. Speaking and teaching: Abbvie, Alfasigma, Gilead, Intercept, Merck and Mylan. Marina Berenguer: Grant and research support: Gilead. Advisory Boards: Abbvie, Gilead and Intercept. Speaking and teaching: Abbvie, Astellas, Intercept and Novartis. Olav Dalgard: Grant and research support: Abbvie, Gilead and Merck. Advisory Boards: Gilead and Merck. Speaking and teaching: Abbvie and Merck. Geoffrey Dusheiko: Grant and research support: Abbott, Cepheid, Gilead and Merck. Advisory Boards: Abbott, Arbutus, Gilead. Safety monitoring boards: Enanta and Janssen. Speaking and teaching: Cepheid and Gilead. Fiona Marra: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Gilead, Merck and Viiv. Speaking and teaching: Abbvie, Gilead and Merck. Francesco Negro: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Gilead and Merck. Speaking and teaching: Abbvie and Gilead. Massimo Puoti: Grant and research support: Cepheid, Gilead, Merck and Viiv. Advisory Boards: Abbvie, Bristol-Myers Squibb, Gilead, Merck and Viiv. Speaking and teaching: Abbvie, Beckman-Coulter, Bristol-Myers Squibb, Correvio, Gilead, Janssen, Merck, Nordic Pharma, Pfizer, Roche, Roche Diagnostics and Viiv. Heiner Wedemeyer: Grant and research support: Abbott, Abbvie, Bristol-Myers Squibb, Gilead, Novartis and Roche Diagnostics. Advisory Boards: Abbott, Abbvie, Bayer, Bristol-Myers Squibb, Eiger, Gilead, Intercept, Janssen, Merck, Myr GmbH, Novartis and Roche Diagnostics. Speaking and teaching: Abbott, Abbvie, Bristol-Myers Squibb, Falk Foundation, Gilead, Novartis, Roche Diagnostics and Siemens. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.J Hepatol. 2021 Feb;74(2):473-474. doi: 10.1016/j.jhep.2020.10.013. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33223214 No abstract available.
-
Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".J Hepatol. 2021 Feb;74(2):474-475. doi: 10.1016/j.jhep.2020.10.025. Epub 2020 Nov 20. J Hepatol. 2021. PMID: 33229012 No abstract available.
Similar articles
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
-
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.BMC Public Health. 2009 Jan 22;9:34. doi: 10.1186/1471-2458-9-34. BMC Public Health. 2009. PMID: 19161623 Free PMC article. Review.
-
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072. Liver Transpl. 2010. PMID: 20517909
-
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.World J Gastroenterol. 2014 Aug 28;20(32):11069-79. doi: 10.3748/wjg.v20.i32.11069. World J Gastroenterol. 2014. PMID: 25170196 Free PMC article. Review.
-
Infections and organ transplantation: new challenges for prevention and treatment of hepatitis C virus.Transplant Proc. 2011 Jul-Aug;43(6):2455-6. doi: 10.1016/j.transproceed.2011.06.017. Transplant Proc. 2011. PMID: 21839292 Review.
Cited by
-
The Role of Sex in Acute and Chronic Liver Damage.Int J Mol Sci. 2022 Sep 13;23(18):10654. doi: 10.3390/ijms231810654. Int J Mol Sci. 2022. PMID: 36142565 Free PMC article. Review.
-
Hepatitis C virus micro-elimination: Where do we stand?World J Gastroenterol. 2021 Apr 28;27(16):1728-1737. doi: 10.3748/wjg.v27.i16.1728. World J Gastroenterol. 2021. PMID: 33967553 Free PMC article. Review.
-
Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study.Euro Surveill. 2024 Jul;29(29):2300712. doi: 10.2807/1560-7917.ES.2024.29.29.2300712. Euro Surveill. 2024. PMID: 39027941 Free PMC article.
-
High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.Pharmacol Res Perspect. 2024 Oct;12(5):e70007. doi: 10.1002/prp2.70007. Pharmacol Res Perspect. 2024. PMID: 39279288 Free PMC article.
-
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.JHEP Rep. 2024 Feb 7;6(3):100994. doi: 10.1016/j.jhepr.2023.100994. eCollection 2024 Mar. JHEP Rep. 2024. PMID: 38357421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical